CellSource Co Stock

CellSource Co Equity

The The Equity of CellSource Co (4880.T) as of Aug 24, 2026 is 6.02 B JPY. In the previous year, The Equity was 6.04 B JPY — a change of -0.34% (lower).

Equity

6.02 BJPY

YoY

-0.34%

Last updated:

In 2026, CellSource Co's equity was 6.02 B JPY, a -0.34% increase from the 6.04 B JPY equity in the previous year.

The CellSource Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
401.25 M JPY
Jan 1, 2019
1.61 B JPY
Jan 1, 2020
2.04 B JPY
Jan 1, 2021
2.72 B JPY
Jan 1, 2022
3.79 B JPY
Jan 1, 2023
6.20 B JPY
Jan 1, 2024
6.04 B JPY
Jan 1, 2025
6.02 B JPY
The CellSource Co Equity history
YEAREquityYoY
6.02 BJPY-0.34%
6.04 BJPY-2.66%
6.20 BJPY+63.83%
3.79 BJPY+39.16%
2.72 BJPY+33.19%
2.04 BJPY+27.05%
1.61 BJPY+300.67%
401.25 MJPY+93.05%
207.85 MJPY—
Access this data via the Eulerpool API
Get Free API Key

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing CellSource Co's Equity

CellSource Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding CellSource Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating CellSource Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

CellSource Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in CellSource Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about CellSource Co stock

The Equity of CellSource Co is 6.02 B JPY in 2026.

The Equity of CellSource Co changed from 6.04 B JPY to 6.02 B JPY, representing a -0.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity CellSource Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's CellSource Co historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — CellSource Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — CellSource Co